Connect with us

business

Kratom Industry Requesting Some Government Regulation  

Published

on


While you would think most industries would jump at the chance to operate in an unregulated market, where they can do whatever they want, it seems that model doesn’t work for everyone. Companies who are trying to be honest and actually have some integrity in their products are being overshadowed by an influx of fake, adulterated, and sometimes dangerous products that are infiltrating the market, and casting a bad light on the industry as whole.  

As a result, the American Kratom Association along with several individual companies are requesting help in the form of government regulation to work on getting sketchy products off the shelves. 

What is Kratom? 

Kratom (Mitragyna speciosa) is a flowering evergreen tree related to the coffee plant. It is indigenous to Southeast Asia but has been gaining popularity in western culture for its stimulating and pain-relieving effects. Kratom is used both recreationally and therapeutically, and just like cannabis, it’s incredibly controversial. Quite a few studies have noted the pharmaceutical potential of Kratom. Kratom is made up of dozens of alkaloids, compounds which are known to hold medicinal value and have been studied independently for decades.  

Alkaloids are a class of basic, naturally occurring organic compounds that contain at least one nitrogen atom. They are produced by a large variety of organisms including bacteria, fungi, plants, and animals and can be purified from crude extracts of these organisms by acid-base extraction, or solvent extractions followed by silica-gel column chromatography. Alkaloids have a wide range of pharmacological activities and there is a lot of existing research to back this up.  

The most abundant alkaloid in Kratom is mitragynine, and for decades it was also believed to be the most potent. Then in 2002, a group of Japanese researchers found a variant called 7-hydronitragynine. This minor compound is extremely potent, more powerful than morphine, and despite being found only in trace amounts, it’s responsible for most of kratom’s pain-fighting properties. Further research has determined that both alkaloids act as partial opioid receptor agonists by activating the supraspinal mu- and delta- opioid receptors.  

Kratom effects vary greatly based on the dosage. Low doses result in stimulant effects, whereas high doses produce sedative, opiate-like effects. Typically, the leaves are crushed then smoked, brewed in a tea, or used in capsules. It’s still used widely in Southeast Asia, from where it originates, and there it is referred to as thang, kakuam, thom, ketum, and biak. In the US, it’s simply known as Kratom, and while it’s still a bit of fringe product, it is growing in popularity here as well.  

Is kratom legal? 

The short answer, it’s complicated. Although it’s technically legal at the federal level, they way it’s usually marketed is illegal because the FDA has not approved kratom for any specific use. So selling as a random smoke shop item is fine, but selling it and saying it can help with pain and boost energy is not allowed.  

Kratom leaves are often ground into a fine powder and used in capsules

Regardless, it can be found everywhere from convenience stores and gas stations, wellness stores, smoke shops, and the world wide web, so as much as the FDA wants to say it has no therapeutic value, that’s not stopping people from using it. As such, the US Drug Enforcement Agency (DEA) has been trying to add kratom the Schedule I list of controlled substances (like cannabis which they say is dangerous, but not cocaine which is safer as a Schedule II); albeit, unsuccessfully.  

Their position has been met with resistance from industry stakeholders, researchers, and consumers alike. In August 2016, the DEA attempted to temporarily reclassify kratom, and due to public demonstrations, petitions, and calls by Congress to overrule their decision, they changed their tune and retracted the reclassification in October 2016, only 2 months later.  

Now, individual states are beginning to make their own laws regarding kratom use. Similar to how states have been granted the authority to regulate cannabis use, despite it going against federal regulations, states are taking similar actions to either protect or prohibit kratom.  

We also have the Kratom Consumer Protection Act (KCPA), a bill drafted by the American Kratom Association, that aims to progressively regulate the US kratom industry. The act is currently under review by several state governments, and the Kratom association is attempting to get more states to adopt better kratom policies. Although this act has been in the works for years, it has not been covered extensively by the mainstream media.  

The bill addresses all topics relating to the growing kratom industry, such as: cultivation, manufacture, distribution, medical benefits, sale, possession, use, age limits, testing, labeling, fines and penalties. Overall, the main purpose of the Kratom Consumer Protection Act is to protect customers from shady companies, and ensure that kratom producers and vendors are only supplying safe, high-quality products that are free of pesticides, heavy metals, fungus, and other contaminants. 

As of now, kratom is expressly banned in the following states: Alabama, Arkansas, Indiana, Rhode Island, Vermont, and Wisconsin. Certain cities also prohibit the sale, possession and use of kratom: Oceanside, CA, San Diego, CA, Sarasota, FL, Jerseyville, IL, and Union County, MS. 

In a change of pace, the industry requests help from the government  

Because the industry is so unregulated, and downright confusing, business owners are facing an onslaught of import alerts, warning letters, and product seizures. All this legal action has those in the kratom industry who are trying to remain honest, crying out for help in the form of government regulation.  

In the most recent news, this summer, a jury awarded the family of Florida woman $11 million in a wrongful death suit. According to court documents, the woman died from “acute mitragynine intoxication,” which is one of the primary compounds found in kratom. The 39-year-old woman, who had been using kratom for pain management, collapsed and died while cooking breakfast one morning in June 2021. It was determined that the kratom she was using, from Grow LLC, was the cause, although I couldn’t find anywhere if it was related to mislabeling, improper dosing, tainted product, or user error. 

Many products in the kratom industry are contaminated

Regardless, the case emphasized to the public that kratom can be dangerous, and that it “produces classic opioid-like effects at high concentrations, such as sedation, nausea, vomiting, addiction, and difficulty breathing, which may be fatal.” 

Stories like this have consumers rightfully skeptical, so in response, the American Kratom Association issued a statement requesting the following:  

  1. Urges the FDA to immediately publish product manufacturing standards for kratom products that are sold to consumers and encourage the removal of kratom products that do not contain adequate labeling with recommended serving sizes, product ingredients, and appropriate warnings on conditions of use.  
  2. Until the FDA implements a set of standards to protect consumers, the AKA advises kratom consumers not to purchase or consume kratom products that:  
    • Have not been certified by an independent third-party lab to be free of dangerous contaminants or contain adulterants that could be dangerous to consume.  
    • Are offered for sale from a vendor that markets its product with illegal therapeutic claims.  
    • Do not contain the name of the product distributor so that a consumer can file an adverse event report if required.  
    • Are delivered in unprofessional packaging, such as zip-close bags, or that have handwritten product information.

“Recent reports of product liability awards for irresponsibly manufactured or marketed kratom products are the direct result of the FDA’s failure to regulate the kratom marketplace and, in some cases, the exploitive behavior of trial attorneys who do nothing to compel the FDA to act responsibly,” said Mac Haddow, the AKA’s Senior Fellow on Public Policy.

“The AKA supports congressional action to compel the FDA to develop and implement a set of standards for the manufacturing and marketing of kratom products to protect consumers in the United States,” he added.  

Final thoughts on kratom regulation

Kratom regulation is a confusing topic. It’s similar to the early days of CBD when the government was issuing warning letters to companies who claimed cannabidiol can be used to treat various health conditions. If the government steps in, it’s possible that kratom will become less accessible to consumers, but hopefully it means that the products they do find are safer and more effective.

Hello readers. We’re happy to have you with us at Cannadelics.com; a news source here to bring you the best in independent reporting for the growing cannabis and hallucinogen fields. Join us frequently to stay on top of everything, and subscribe to our Cannadelics Weekly Newsletter, for updates straight to your email. Check out some awesome promos for cannabis buds, smoking devices and equipment like vapes, edibles, cannabinoid compounds, amanita mushroom products, and a whole bunch more. Let’s all get stoned together!



Source link

Continue Reading

business

Marijuana rescheduling leaves regulators and sellers cautiously optimistic

Published

on

By



A move by the Biden Administration to change how marijuana is treated by federal authorities was met with cautious approval by Massachusetts state regulators, cannabis sellers, and national marijuana advocates alike.

The Drug Enforcement Agency will drop marijuana from the list of banned substances found under Schedule I of the Controlled Substances Act, where it currently sits alongside heroin and LSD. It will instead move it to Schedule III, among the likes of Tylenol with codeine and anabolic steroids. This follows the recommendation of the Department of Health and Human Services

“Rescheduling cannabis is a monumental step forward for the federal government, one that can open new avenues to research, medical use, and banking for the regulated industries states like Massachusetts have built across the country,” said Ava Callender Concepcion, the acting chair of the Bay State’s Cannabis Control Commission.

Read the rest of this story on BostonHerald.com.



Source link

Continue Reading

business

Thailand Considers Relisting Cannabis as a Narcotic

Published

on

By


The Thai government is contemplating the relisting of cannabis as a narcotic due to concerns over its recreational use and potential societal harms. This reconsideration comes after cannabis was decriminalized in June 2022, which led to a surge in its availability and use.

Cannabis Conundrum: Thailand Reconsiders Legal Status Amidst Rising Concerns

The recent decriminalization of cannabis in Thailand has ignited a complex debate over its legal status and societal impact. While the policy aimed to boost the medical marijuana industry and provide economic opportunities, the unintended rise in recreational use has sparked discussions about a potential reclassification.

Public Health Minister Anutin Charnvirakul, a key advocate for the decriminalization, emphasized that the policy was intended to promote medical use, not recreational. However, the current legal framework lacks clear regulations governing recreational use, leading to widespread availability and potential misuse.

The Bhumjaithai Party, led by Anutin, initially pushed for the delisting of cannabis to benefit the medical industry and provide economic opportunities for Thai citizens. However, the subsequent surge in recreational use, particularly among youths, has raised concerns about potential health and social consequences.

Opposition parties have criticized the government for inadequate regulations and are advocating for cannabis to be relisted as a narcotic under the Narcotics Act. They argue that the current situation exposes young people to potential harm and lacks sufficient safeguards.

A recent poll revealed that a majority of Thais support stricter regulations on cannabis use. Concerns have been raised about the potential impact on public health, particularly regarding mental health issues and addiction, especially among youths. Additionally, there are worries about the potential for increased crime and social disorder.

The government now faces the challenge of balancing the economic benefits of a burgeoning cannabis industry with the need to protect public health and safety. Finding a solution that addresses the concerns of both advocates and critics will be crucial in determining the future of cannabis in Thailand

Why It Matters

Thailand’s shift in cannabis policy has garnered international attention, serving as a case study for the complexities of drug policy reform. The potential reclassification of cannabis underscores the challenges of balancing economic opportunities with public health and safety considerations. The outcome of this debate will have significant implications for Thailand’s legal landscape, public health policies, and the future of its cannabis industry.

Potential Implications of Relisting Cannabis as a Narcotic

If cannabis is relisted as a narcotic, it could lead to stricter regulations on its cultivation, distribution, and use. This may impact the growth of the medical marijuana industry and limit access for patients who rely on cannabis for therapeutic purposes. Additionally, it could result in increased criminal penalties for possession and use, potentially leading to a rise in incarceration rates.

Alternatively, if the government opts to maintain the decriminalized status, it will need to implement robust regulations and public health campaigns to mitigate the risks associated with recreational use. This includes age restrictions, educational initiatives, and support systems for individuals struggling with cannabis dependence.

The Bigger Picture

The debate surrounding cannabis legalization and regulation is a global phenomenon, with countries around the world grappling with similar challenges. The Thai government’s decision regarding cannabis will likely be influenced by international trends and best practices in drug policy reform. It is crucial to consider the experiences of other nations that have legalized or decriminalized cannabis, examining both the successes and challenges they have encountered.

Source: Thai PBS World



Source link

Continue Reading

banking

“A big deal”: What the feds’ move to reclassify marijuana means for Colorado cannabis

Published

on

By



Cannabis advocates in Colorado cheered the Biden Administration’s reported move to reclassify marijuana and said the decision likely would reduce businesses’ tax burden significantly.

Industry leaders cautioned that such a move — if finalized — would not resolve some major challenges facing the industry, such as limited access to banking. But they pointed to the symbolic importance of preparations by the U.S. Drug Enforcement Administration to downgrade the substance’s drug classification.

A man pours cannabis into rolling papers as he prepares to roll a joint the Mile High 420 Festival in Civic Center Park in Denver, April 20, 2024. (Photo by Kevin Mohatt/Special to The Denver Post)

Read the rest of this story on DenverPost.com.



Source link

Continue Reading
Advertisement

Trending

Copyright © 2021 The Art of MaryJane Media